Andrew Penkethman – CEO & Managing Director – Ardea Resources (ASX:ARL) is an ASX-listed nickel resources company, with a large portfolio of 100%-controlled West Australian-based projects.
Copyright 2024 – Finance News Network
Source: Finance News Network
17 May 2021 - Melbana Energy Limited (ASX:MAY) Executive Chairman Andrew Purcell provides an update on the company's key Cuban onshore oil project, including preparation for its two exploration well program scheduled for Q3 2021 and its sale of WA-488-P permit (containing the Beehive Prospect) to a wholly owned Australian subsidiary of the US company EOG Resources, Inc (NYSE:EOG).
Read More27 Apr 2022 - Acorn Capital Investment Fund (ASX:ACQ) Portfolio Manager Rick Squire discusses key factors behind commodity demand and which commodities to keep an eye on.
Read More16 Jun 2020 - Zelira Therapeutics Limited (ASX:ZLD) Managing Director Ex USA, Dr Richard Hopkins talks about the company's pipeline of products in clinical development targeting insomnia, chronic pain and autism, its model for rapid commercialisation, its go-to-market strategy and first revenues from US licensing partners.
Read More04 Oct 2022 - Knosys Limited (ASX:KNO) Managing Director John Thompson discusses FY22 highlights, revenue drivers, growth investments, hybrid working tailwinds and the outlook for FY23.
Read More01 Apr 2022 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari introduces the company, discussing the use of radiopharmaceuticals for cancer treatment and the company's upcoming trial in non-small cell lung cancer.
Read More08 Jul 2021 - ImpediMed Limited (ASX:IPD) CEO and Managing Director Richard Carreon discusses the company's bioimpedance spectroscopy platform SOZO, which is particularly targeted at noninvasive clinical assessment and monitoring of fluid status and tissue composition in the treatment of secondary lymphoedema, heart failure and renal failure.
Read More19 Aug 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress with the company's IMP761 drug, which is potentially active in more than 90% of autoimmune diseases.
Read More17 Sep 2019 - Tinybeans Limited (ASX:TNY) Founder & CEO, Eddie Geller discusses the company's FY19 results, growth users to its platform, new services and strategy.
Read More03 Nov 2023 - NOVONIX (ASX:NVX) CEO, Chris Burns, discusses securing a $100 million grant from the DOE, the company's Riverside facility expansion, graphite's future amidst China's export controls, and the pivotal role of synthetic graphite in clean energy.
Read More01 May 2020 - Acorn Capital, Head of Portfolio Implementation and Portfolio manager (Healthcare and Biotechnology sectors) Paul Palumbo looks the microcap sector and the recent market sell off and discusses the outlook for next 6 months and longer term.
Read More
